SCHEMBL3084783

SCHEMBL3084783

CCN(CC)C(=O)C(CCc1ccc(NC(=O)c2c(N)cccc2F)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.40
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
KAT6A Q92794 5/20 0.38
F2 P00734 3/20 0.37
TPSAB1 Q15661 3/20 0.37
KMT2A Q03164 3/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MEN1 O00255 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KAT7 O95251 1/20 0.35
CYP2D6 P10635 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089105 0.96 LARS1 (0.40) LARS1LMNATP53MAPTKAT6A
SCHEMBL3100804 0.92 F2 (0.42) LARS1LMNATP53MAPTKAT6A
SCHEMBL3096609 0.92 F2 (0.42) LARS1LMNATP53MAPTKAT6A
SCHEMBL3096740 0.87 LARS1 (0.41) LARS1LMNATP53MAPTKAT6A
SCHEMBL3079467 0.86 F2 (0.43) LARS1LMNATP53MAPTKAT6A
SCHEMBL3099763 0.86 LARS1 (0.40) LARS1LMNATP53MAPTKAT6A
SCHEMBL3091266 0.85 LMNA (0.44) LARS1LMNAMAPTKAT6AKMT2A
SCHEMBL15000268 0.83 LARS1 (0.50) LARS1LMNAKAT6AF2TPSAB1
SCHEMBL3088704 0.83 LARS1 (0.40) LARS1LMNATP53MAPTKAT6A
SCHEMBL3100500 0.82 NPC1 (0.49) LARS1LMNATP53MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885LMNA 3803/4885TP53 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.